Home » Healthcare » Pharmaceuticals » Peptic Ulcer Drugs Market

Peptic Ulcer Drugs Market By Drugs (Proton Pump Inhibitors (PPIs), H2 Antagonists, Antibiotics, Others); By Type (Gastric Ulcers, Duodenal Ulcers); By Region – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Peptic Ulcer Drugs Market Size 2023	USD 5,321.98 Million
Peptic Ulcer Drugs Market, CAGR	4.80%
Peptic Ulcer Drugs Market Size 2032	USD 8,115.68 Million

Market Overview

The peptic ulcer drugs market is projected to grow from USD 5,321.98 million in 2023 to an estimated USD 8,115.68 million by 2032, with a compound annual growth rate (CAGR) of 4.80% from 2024 to 2032. This growth reflects a rising prevalence of peptic ulcers globally, driven by lifestyle changes, stress, and increased use of NSAIDs and other medications that can contribute to gastric conditions.

Market drivers include a growing aging population, heightened awareness of gastrointestinal diseases, and advancements in drug formulations and delivery systems. Trends within this market emphasize the development of combination therapies and personalized treatments, targeting Helicobacter pylori (H. pylori) infections, a major causative factor for ulcers. Increased R&D investments are also leading to innovations in drug development, aiming to enhance efficacy, reduce side effects, and address antibiotic resistance, which remains a significant concern in treating H. pylori infections.

Geographically, North America leads the market due to high healthcare expenditure and awareness, followed closely by Europe and Asia-Pacific. The Asia-Pacific region, particularly China and India, is expected to witness the fastest growth owing to a large patient pool and increasing healthcare infrastructure. Key players in the peptic ulcer drugs market include AstraZeneca, Takeda Pharmaceutical Company, Pfizer Inc., and Abbott Laboratories, who are actively investing in research to maintain their competitive edge.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Drivers

Increasing Prevalence of Peptic Ulcers and Associated Risk Factors

The rising prevalence of peptic ulcers globally, especially in both developed and emerging markets, is a primary driver for the peptic ulcer drugs market. This increase is largely due to lifestyle-related factors such as stress, poor dietary habits, smoking, and alcohol consumption, which are known to exacerbate gastric issues. The widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin, particularly among the elderly population, further contributes to the incidence of peptic ulcers, as these medications can erode the stomach lining and lead to ulcer formation. Additionally, infections from Helicobacter pylori (H. pylori) bacteria, a major cause of peptic ulcers, remain prevalent in many regions, especially in low- and middle-income countries with limited access to healthcare services and sanitation. This growing patient population is driving the demand for effective peptic ulcer medications that can manage symptoms, treat infections, and reduce recurrence. For instance, a global study published in the International Journal of Epidemiology found that the prevalence of peptic ulcer disease increased from 6,434,103 cases in 1990 to 8,090,476 cases in 2019, indicating a significant rise in the number of people affected by this condition worldwide over a 30-year period.

Advancements in Drug Development and Therapy

Innovations in the pharmaceutical sector are significantly enhancing treatment options for peptic ulcer patients, driving market growth. Major pharmaceutical companies are investing heavily in research and development to produce more effective and targeted treatments with fewer side effects, as well as combination therapies that address multiple facets of ulcer disease management. Advances in drug formulation and delivery methods, such as controlled-release and extended-release medications, aim to improve patient compliance and the overall therapeutic experience. Additionally, drug developers are working on therapies that specifically target H. pylori, the primary bacterial agent responsible for most peptic ulcers. Addressing antibiotic resistance, which has become a critical issue in treating H. pylori infections, is a key focus area for many research initiatives. Through these innovations, pharmaceutical companies aim to bring more efficacious treatments to market, catering to a larger patient base and driving growth.

Increasing Awareness and Access to Treatment

Greater awareness of gastrointestinal health issues, coupled with increased access to healthcare services, is boosting the demand for peptic ulcer drugs. Educational campaigns and awareness programs are being conducted by healthcare organizations and pharmaceutical companies to highlight the importance of early detection and treatment of peptic ulcers. Early diagnosis allows for timely treatment, which can prevent complications and reduce hospitalizations, thereby decreasing the overall burden on healthcare systems. Access to treatment is also expanding in emerging economies where healthcare infrastructure is improving, and health insurance coverage is broadening. In addition, telemedicine and online pharmacy services are playing a crucial role in increasing patient access to peptic ulcer medications, particularly in remote and underserved areas. This expansion of healthcare access and awareness is leading to more individuals seeking diagnosis and treatment, further propelling the market.

Aging Population and Growth in the Elderly Demographic

The global increase in the aging population is another major factor driving demand for peptic ulcer drugs. Aging is associated with a higher likelihood of developing gastric issues, including peptic ulcers, due to factors such as a weakened stomach lining, decreased immunity, and a higher incidence of chronic conditions that require long-term NSAID use. Older adults are also more likely to have compromised health and face difficulties recovering from peptic ulcers without medical intervention. As a result, the elderly demographic represents a significant portion of the patient population in need of effective and safe peptic ulcer treatments. With the world’s elderly population growing rapidly, especially in regions like North America, Europe, and Asia-Pacific, this demographic trend is expected to drive sustained demand for peptic ulcer drugs over the coming years. Pharmaceutical companies and healthcare providers are increasingly focusing on the needs of elderly patients by developing formulations that are easier to administer and minimize side effects, thereby enhancing the treatment options available to this crucial patient group.

Market Trends

Growing Focus on Targeted Therapies and Combination Treatments

One significant trend in the peptic ulcer drugs market is the increasing focus on targeted therapies and combination treatments, especially to address Helicobacter pylori (H. pylori) infections—a primary cause of peptic ulcers. Given the rising concerns around antibiotic resistance, drug developers are exploring combination therapies that can simultaneously target multiple mechanisms involved in ulcer formation and progression. These treatments often pair antibiotics with proton pump inhibitors (PPIs) or histamine H2-receptor antagonists to manage stomach acid production, thereby enhancing the effectiveness of the treatment while minimizing the risk of recurrence. For instance, a clinical study involving 1,000 patients with H. pylori-associated peptic ulcers showed that a combination therapy of amoxicillin, clarithromycin, and a proton pump inhibitor administered for 14 days resulted in an eradication rate of 85%, compared to a 70% eradication rate with standard dual therapy. Additionally, advances in drug delivery systems, such as controlled-release formulations, are enabling sustained medication action, reducing the frequency of dosing and increasing patient compliance. Targeted therapies are also being developed to minimize side effects, a common issue in peptic ulcer treatment, especially for patients who may be on long-term medication regimens. The trend toward personalized treatment options is shaping the market by offering solutions that address individual patient needs more effectively.

Increasing Role of Digital Health Solutions in Diagnosis and Treatment

The integration of digital health solutions in the diagnosis, treatment, and management of peptic ulcers is a trend that’s gaining traction across the healthcare industry. Telemedicine platforms and online consultations are making it easier for patients to access timely medical advice, diagnosis, and prescriptions for peptic ulcer treatments. For instance, a telemedicine platform specializing in gastrointestinal disorders reported facilitating over 50,000 virtual consultations for peptic ulcer patients in 2023, with 80% of these patients receiving timely diagnoses and treatment plans without the need for in-person visits. Digital health solutions also allow healthcare providers to monitor patient adherence to medication regimens, which is crucial in peptic ulcer management to prevent relapse and complications. Additionally, digital platforms that provide access to online pharmacies are ensuring that patients, even in remote or underserved regions, can obtain essential medications. The availability of digital health tools has also boosted awareness campaigns for gastrointestinal health, emphasizing preventive measures and early diagnosis. With more individuals adopting digital health tools, this trend is helping expand access to treatment and improve patient outcomes, ultimately driving demand in the peptic ulcer drugs market.

Market Restraints and Challenges

Rising Antibiotic Resistance Complicating Treatment Effectiveness

One major challenge in the peptic ulcer drugs market is the growing issue of antibiotic resistance, particularly concerning treatments targeting Helicobacter pylori (H. pylori), a leading cause of peptic ulcers. Over time, the widespread use of antibiotics has led to resistant strains of H. pylori, complicating treatment protocols and reducing the efficacy of traditional therapy options. This resistance requires the development of new antibiotic combinations or alternative therapeutic approaches, both of which demand significant investment in research and development. Moreover, resistant strains can lead to increased recurrence rates, as standard treatments may fail to fully eradicate the infection. For pharmaceutical companies, addressing antibiotic resistance requires balancing the high costs of R&D with uncertain returns, especially as regulatory hurdles for new antibiotics can delay product launches. This resistance challenge not only affects treatment outcomes but also increases the financial burden on healthcare providers and patients, impacting overall market growth.

Side Effects and Compliance Issues Associated with Long-term Medication Use

Another key restraint in the peptic ulcer drugs market is the side effects associated with long-term use of peptic ulcer medications, particularly proton pump inhibitors (PPIs) and H2-receptor antagonists. While these drugs are effective in reducing stomach acid, prolonged use has been linked to adverse effects such as nutrient malabsorption, kidney issues, and an increased risk of bone fractures. These side effects can deter patients from adhering to prescribed treatment regimens, impacting overall treatment effectiveness and increasing the risk of ulcer recurrence. Additionally, compliance issues often arise with combination therapies, as patients may find it challenging to manage multiple medications, leading to lower adherence rates. Pharmaceutical companies are focusing on improving formulations to reduce side effects, but this process is costly and time-intensive. As a result, the challenge of side effects and patient compliance remains a significant barrier to sustained market growth, affecting both patient outcomes and market dynamics.

Market Segmentation Analysis

By Drugs

Proton Pump Inhibitors (PPIs) like omeprazole and esomeprazole dominate the peptic ulcer drugs market due to their effectiveness in reducing stomach acid and promoting ulcer healing, with ongoing R&D improving formulations to reduce side effects and enhance patient compliance. H2 antagonists, such as ranitidine and famotidine, offer an alternative for patients sensitive to PPIs by inhibiting histamine action to reduce acid production, though they are less commonly used. Antibiotics are crucial for treating Helicobacter pylori (H. pylori)-induced ulcers by addressing the underlying infection, often in combination with PPIs, though antibiotic-resistant H. pylori strains present a significant challenge, prompting the need for innovative treatment approaches. The “Others” category includes cytoprotective agents and antacids, which are frequently used as adjunct therapies to manage symptoms and offer short-term relief, particularly in over-the-counter settings, even though they do not address the root cause of ulcers.

By Type

Gastric and duodenal ulcers represent key segments within the peptic ulcer drugs market. Gastric ulcers, which form on the stomach lining, are often linked to lifestyle factors such as smoking, alcohol use, and NSAID consumption, resulting in high demand for treatments like PPIs and H2 antagonists to manage recurrent symptoms. Meanwhile, duodenal ulcers, occurring in the small intestine, are commonly associated with H. pylori infections and are primarily treated with antibiotics in combination with acid-suppressing drugs. Given the high prevalence of H. pylori in certain regions, the duodenal ulcer segment shows strong growth potential, especially in areas where bacterial infections are more widespread.

Segments

Based on Drugs

Proton Pump Inhibitors (PPIs)
H2 Antagonists
Antibiotics
Others

Based on Type

Gastric Ulcers
Duodenal Ulcers

Based on Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Regional Analysis

North America (35%):

North America holds the largest market share, accounting for approximately 35% of the global peptic ulcer drugs market. This dominance is driven by high healthcare expenditure, advanced medical infrastructure, and widespread awareness of gastrointestinal diseases. Additionally, the region has a large aging population, which is more susceptible to conditions that increase the risk of peptic ulcers, such as the regular use of NSAIDs. The U.S. leads the North American market, with major pharmaceutical companies actively investing in research to improve drug efficacy and address rising antibiotic resistance issues associated with H. pylori infections.

Europe (27%):

Europe follows closely with a market share of around 27%. The region’s high prevalence of peptic ulcers, particularly in the elderly population, contributes to substantial demand for ulcer medications. Countries like Germany, the UK, and France are key contributors to the European market due to their strong healthcare systems and high awareness of gastrointestinal health. Additionally, Europe’s proactive approach toward research and development, alongside collaborations among pharmaceutical companies and research institutions, supports ongoing advancements in peptic ulcer treatments. However, stringent regulatory policies in Europe present a challenge, making market entry slightly more complex for newer therapies.

Key players

AstraZeneca
Novartis AG
Pfizer Inc.
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Mylan Pharmaceuticals Inc.
Abbott
Zydus Cadila

Competitive Analysis

The peptic ulcer drugs market is highly competitive, with several global and regional players vying for market share. AstraZeneca, Pfizer Inc., and GlaxoSmithKline plc lead the market with strong product portfolios and significant R&D investments aimed at developing advanced therapies. AstraZeneca, for example, holds a competitive edge due to its robust product range and strategic focus on innovation. Takeda Pharmaceutical and Novartis AG also have substantial market influence, particularly in regions like Asia-Pacific, where they focus on expanding access to treatment options.Mylan Pharmaceuticals and Zydus Cadila contribute by providing cost-effective solutions, which are especially popular in price-sensitive markets. Abbott is known for its wide-reaching distribution networks, making it a strong competitor in emerging markets. Overall, these companies compete by leveraging product differentiation, strategic geographic expansions, and continual innovation to meet rising demand and address challenges like antibiotic resistance in the peptic ulcer drugs market.

Recent Developments

In March 2023, Pfizer received U.S. FDA approval for VELSIPITY (etrasimod), a selective S1P receptor modulator for adults with moderately to severely active ulcerative colitis (UC). Although primarily for UC, this development is relevant due to the overlap in gastrointestinal treatment areas.
In December 2023, Mylan expanded its gastroenterology portfolio by launching a generic version of Prevacid SoluTab, known as Lansoprazole Delayed-Release Orally Disintegrating Tablets. These are approved for treating certain types of gastrointestinal ulcers.
In November 2023, Takeda signed a non-exclusive patent license agreement with Lupin Ltd to commercialize Vonoprazan tablets in India. This novel treatment option is used for acid peptic disorders, including gastric and duodenal ulcer.

Market Concentration and Characteristics

The peptic ulcer drugs market is moderately concentrated, with a few key players holding significant shares due to their strong portfolios of advanced therapies and established global distribution networks. Companies like AstraZeneca, Pfizer, and Takeda Pharmaceutical dominate, driven by their continuous R&D investments and innovative treatment solutions aimed at enhancing efficacy and addressing issues like antibiotic resistance. The market is characterized by a mix of patented drugs and generics, offering treatment options across various price ranges, which appeals to both developed and emerging markets. Additionally, the market sees a high level of strategic partnerships and mergers aimed at expanding product pipelines and geographic reach. Despite strong competition among established brands, regional players and generics manufacturers play a crucial role in catering to cost-sensitive regions, highlighting the market’s diverse price dynamics and growing focus on affordable, effective treatments.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Drugs, Type and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The peptic ulcer drugs market is expected to grow steadily, driven by rising incidence rates and increasing awareness about gastrointestinal health.
Pharmaceutical companies will continue investing in targeted therapies, focusing on reducing recurrence and side effects for better patient outcomes.
Combination therapies, particularly for H. pylori-induced ulcers, will see increased adoption as they improve treatment efficacy and address antibiotic resistance.
New drug delivery systems, such as controlled-release formulations, will improve patient adherence by minimizing dosing frequency and enhancing therapeutic effects.
Digital health platforms and telemedicine will expand access to diagnosis and treatment, especially in remote areas, supporting market growth.
Emerging markets in Asia-Pacific, Latin America, and the Middle East will drive demand, as improving healthcare infrastructure enables better access to treatments.
With antibiotic resistance on the rise, there will be a significant push toward developing alternative treatments to combat H. pylori infections effectively.
The global increase in the elderly population will sustain demand for peptic ulcer drugs, as this demographic is more prone to ulcer-related issues.
The presence of generics, especially in emerging markets, will contribute to market expansion by providing affordable treatment options for wider patient reach.
Regulatory standards for safety and efficacy will become more stringent, prompting companies to focus on compliance and quality assurance to meet evolving market demands.

CHAPTER NO. 1 : INTRODUCTION 30
1.1.1. Report Description 30
Purpose of the Report 30
USP & Key Offerings 30
1.1.2. Key Benefits for Stakeholders 30
1.1.3. Target Audience 31
1.1.4. Report Scope 31
1.1.5. Regional Scope 32
CHAPTER NO. 2 : EXECUTIVE SUMMARY 32
2.1. Peptic Ulcer Drugs Market Snapshot 32
2.1.1. Global Peptic Ulcer Drugs Market, 2018 – 2032 (Unit) (USD Million) 35
2.2. Insights from Primary Respondents 35
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 36
3.1. Russia-Ukraine and Israel-Palestine War Impacts 36
CHAPTER NO. 4 : PEPTIC ULCER DRUGS MARKET – INDUSTRY ANALYSIS 37
4.1. Introduction 37
4.2. Market Drivers 38
4.2.1. Driving Factor 1 Analysis 38
4.2.2. Driving Factor 2 Analysis 39
4.3. Market Restraints 40
4.3.1. Restraining Factor Analysis 40
4.4. Market Opportunities 41
4.4.1. Market Opportunity Analysis 41
4.5. Porter’s Five Forces Analysis 42
CHAPTER NO. 5 : ANALYSIS COMPETITIVE LANDSCAPE 43
5.1. Company Market Share Analysis – 2023 43
5.1.1. Global Peptic Ulcer Drugs Market: Company Market Share, by Volume, 2023 43
5.1.2. Global Peptic Ulcer Drugs Market: Company Market Share, by Revenue, 2023 44
5.1.3. Global Peptic Ulcer Drugs Market: Top 6 Company Market Share, by Revenue, 2023 44
5.1.4. Global Peptic Ulcer Drugs Market: Top 3 Company Market Share, by Revenue, 2023 44
5.2. Global Peptic Ulcer Drugs Market Company Volume Market Share, 2023 46
5.3. Company Assessment Metrics, 2023 47
5.3.1. Stars 47
5.3.2. Emerging Leaders 47
5.3.3. Pervasive Players 47
5.3.4. Participants 47
5.4. Start-ups /SMEs Assessment Metrics, 2023 47
5.4.1. Progressive Companies 47
5.4.2. Responsive Companies 47
5.4.3. Dynamic Companies 47
5.4.4. Starting Blocks 47
5.5. Strategic Developments 48
5.5.1. Acquisitions & Mergers 48
New Product Launch 48
Regional Expansion 48
5.6. Key Players Product Matrix 49
CHAPTER NO. 6 : PESTEL & ADJACENT MARKET ANALYSIS 50
6.1. PESTEL 50
6.1.1. Political Factors 50
6.1.2. Economic Factors 50
6.1.3. Social Factors 50
6.1.4. Technological Factors 50
6.1.5. Environmental Factors 50
6.1.6. Legal Factors 50
6.2. Adjacent Market Analysis 50
CHAPTER NO. 7 : PEPTIC ULCER DRUGS MARKET – BY DRUGS SEGMENT ANALYSIS 51
7.1. Peptic Ulcer Drugs Market Overview, by Drugs Segment 51
7.1.1. Peptic Ulcer Drugs Market Volume Share, By Drugs, 2023 & 2032 52
7.1.2. Peptic Ulcer Drugs Market Revenue Share, By Drugs, 2023 & 2032 52
7.1.3. Peptic Ulcer Drugs Market Attractiveness Analysis, By Drugs 53
7.1.4. Incremental Revenue Growth Opportunity, by Drugs, 2024 – 2032 53
7.1.5. Peptic Ulcer Drugs Market Revenue, By Drugs, 2018, 2023, 2027 & 2032 54
7.2. Proton Pump Inhibitor 55
7.2.1. Global Proton Pump Inhibitor Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 56
7.2.2. Global Proton Pump Inhibitor Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 56
7.3. H2 Antagonists 57
7.3.1. Global H2 Antagonists Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 58
7.3.2. Global H2 Antagonists Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 58
7.4. Antibiotics 59
7.5. Global Antibiotics Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 60
7.6. Global Antibiotics Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 60
7.7. Others 61
7.7.1. Global Others Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 62
7.7.2. Global Others Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 62
7.8. Drugs 5 63
7.8.1. Global Drugs 5 Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 64
7.8.2. Global Drugs 5 Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 64
CHAPTER NO. 8 : PEPTIC ULCER DRUGS MARKET – BY TYPES SEGMENT ANALYSIS 65
8.1. Peptic Ulcer Drugs Market Overview, by Types Segment 65
8.1.1. Peptic Ulcer Drugs Market Volume Share, By Types, 2023 & 2032 66
8.1.2. Peptic Ulcer Drugs Market Revenue Share, By Types, 2023 & 2032 66
8.1.3. Peptic Ulcer Drugs Market Attractiveness Analysis, By Types 67
8.1.4. Incremental Revenue Growth Opportunity, by Types, 2024 – 2032 67
8.1.5. Peptic Ulcer Drugs Market Revenue, By Types, 2018, 2023, 2027 & 2032 68
8.2. Gastric Ulcer 69
8.2.1. Global Gastric Ulcer Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 70
8.2.2. Global Gastric Ulcer Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 70
8.3. Duodenal Ulcer 71
8.3.1. Global Duodenal Ulcer Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 72
8.3.2. Global Duodenal Ulcer Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 72
CHAPTER NO. 9 : PEPTIC ULCER DRUGS MARKET – REGIONAL ANALYSIS 73
9.1. Peptic Ulcer Drugs Market Overview, by Regional Segments 73
9.2. Region 74
9.2.1. Global Peptic Ulcer Drugs Market Volume Share, By Region, 2023 & 2032 74
9.2.2. Global Peptic Ulcer Drugs Market Revenue Share, By Region, 2023 & 2032 74
9.2.3. Peptic Ulcer Drugs Market Attractiveness Analysis, By Region 75
9.2.4. Incremental Revenue Growth Opportunity, by Region, 2024 – 2032 75
9.2.5. Peptic Ulcer Drugs Market Revenue, By Region, 2018, 2023, 2027 & 2032 76
9.2.6. Global Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 77
9.2.7. Global Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 77
9.3. Drugs 78
9.3.1. Global Peptic Ulcer Drugs Market Volume & Revenue, By Drugs, 2018 – 2023 (Unit) (USD Million) 78
9.4. Global Peptic Ulcer Drugs Market Volume & Revenue, By Drugs, 2024 – 2032 (Unit) (USD Million) 78
9.5. Types 79
9.5.1. Global Peptic Ulcer Drugs Market Volume & Revenue, By Types, 2018 – 2023 (Unit) (USD Million) 79
9.5.2. Global Peptic Ulcer Drugs Market Volume & Revenue, By Types, 2024 – 2032 (Unit) (USD Million) 79
9.6. Distribution Channel 80
9.6.1. Global Peptic Ulcer Drugs Market Volume & Revenue, By Distribution Channel, 2018 – 2023 (Unit) (USD Million) 80
9.6.2. Global Peptic Ulcer Drugs Market Volume & Revenue, By Distribution Channel, 2024 – 2032 (Unit) (USD Million) 81
CHAPTER NO. 10 : PEPTIC ULCER DRUGS MARKET – NORTH AMERICA 82
10.1. North America 82
10.1.1. Key Highlights 82
10.1.2. North America Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2032 (Unit) 83
10.1.3. North America Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 84
10.1.4. North America Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 85
10.1.5. North America Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 86
10.1.6. North America Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 87
10.1.7. North America Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 88
10.1.8. North America Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 89
10.1.9. North America Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 90
10.2. U.S. 91
10.3. Canada 91
10.4. Mexico 91
CHAPTER NO. 11 : PEPTIC ULCER DRUGS MARKET – EUROPE 92
11.1. Europe 92
11.1.1. Key Highlights 92
11.1.2. Europe Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2032 (Unit) 93
11.1.3. Europe Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 94
11.1.4. Europe Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 95
11.1.5. Europe Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 96
11.1.6. Europe Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 97
11.1.7. Europe Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 98
11.1.8. Europe Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 99
11.1.9. Europe Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 100
11.2. UK 101
11.3. France 101
11.4. Germany 101
11.5. Italy 101
11.6. Spain 101
11.7. Russia 101
11.8. Belgium 101
11.9. Netherland 101
11.10. Austria 101
11.11. Sweden 101
11.12. Poland 101
11.13. Denmark 101
11.14. Switzerland 101
11.15. Rest of Europe 101
CHAPTER NO. 12 : PEPTIC ULCER DRUGS MARKET – ASIA PACIFIC 102
12.1. Asia Pacific 102
12.1.1. Key Highlights 102
12.1.2. Asia Pacific Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2032 (Unit) 103
12.1.3. Asia Pacific Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 104
12.1.4. Asia Pacific Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 105
12.1.5. Asia Pacific Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 106
12.1.6. Asia Pacific Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 107
12.1.7. Asia Pacific Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 108
12.1.8. Asia Pacific Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 109
12.1.9. Asia Pacific Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 110
12.2. China 111
12.3. Japan 111
12.4. South Korea 111
12.5. India 111
12.6. Australia 111
12.7. Thailand 111
12.8. Indonesia 111
12.9. Vietnam 111
12.10. Malaysia 111
12.11. Philippines 111
12.12. Taiwan 111
12.13. Rest of Asia Pacific 111
CHAPTER NO. 13 : PEPTIC ULCER DRUGS MARKET – LATIN AMERICA 112
13.1. Latin America 112
13.1.1. Key Highlights 112
13.1.2. Latin America Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2032 (Unit) 113
13.1.3. Latin America Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 114
13.1.4. Latin America Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 115
13.1.5. Latin America Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 116
13.1.6. Latin America Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 117
13.1.7. Latin America Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 118
13.1.8. Latin America Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 119
13.1.9. Latin America Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 120
13.2. Brazil 121
13.3. Argentina 121
13.4. Peru 121
13.5. Chile 121
13.6. Colombia 121
13.7. Rest of Latin America 121
CHAPTER NO. 14 : PEPTIC ULCER DRUGS MARKET – MIDDLE EAST 122
14.1. Middle East 122
14.1.1. Key Highlights 122
14.1.2. Middle East Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2032 (Unit) 123
14.1.3. Middle East Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 124
14.1.4. Middle East Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 125
14.1.5. Middle East Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 126
14.1.6. Middle East Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 127
14.1.7. Middle East Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 128
14.1.8. Middle East Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 129
14.1.9. Middle East Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 130
14.2. UAE 131
14.3. KSA 131
14.4. Israel 131
14.5. Turkey 131
14.6. Iran 131
14.7. Rest of Middle East 131
CHAPTER NO. 15 : PEPTIC ULCER DRUGS MARKET – AFRICA 132
15.1. Africa 132
15.1.1. Key Highlights 132
15.1.2. Africa Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2032 (Unit) 133
15.1.3. Africa Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 134
15.1.4. Africa Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 135
15.1.5. Africa Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 136
15.1.6. Africa Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 137
15.1.7. Africa Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 138
15.1.8. Africa Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 139
15.1.9. Africa Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 140
15.2. Egypt 141
15.3. Nigeria 141
15.4. Algeria 141
15.5. Morocco 141
15.6. Rest of Africa 141
CHAPTER NO. 16 : COMPANY PROFILES 142
16.1. AstraZeneca 142
16.1.1. Company Overview 142
16.1.2. Product Portfolio 142
16.1.3. Swot Analysis 142
16.1.4. Business Strategy 142
16.1.5. Financial Overview 143
16.2. Novartis AG 144
16.3. Pfizer Inc. 144
16.4. GlaxoSmithKline plc 144
16.5. Takeda Pharmaceutical Company Limited. 144
16.6. Mylan Pharmaceuticals Inc. 144
16.7. Abbott 144
16.8. Zydus Cadila 144

List of Figures
FIG NO. 1. Global Peptic Ulcer Drugs Market Volume & Revenue, 2018 – 2032 (Unit) (USD Million) 34
FIG NO. 2. Porter’s Five Forces Analysis for Global Peptic Ulcer Drugs Market 41
FIG NO. 3. Company Share Analysis, 2023 42
FIG NO. 4. Company Share Analysis, 2023 43
FIG NO. 5. Company Share Analysis, 2023 43
FIG NO. 6. Company Share Analysis, 2023 43
FIG NO. 7. Peptic Ulcer Drugs Market – Company Volume Market Share, 2023 45
FIG NO. 8. Peptic Ulcer Drugs Market Volume Share, By Drugs, 2023 & 2032 51
FIG NO. 9. Peptic Ulcer Drugs Market Revenue Share, By Drugs, 2023 & 2032 51
FIG NO. 10. Market Attractiveness Analysis, By Drugs 52
FIG NO. 11. Incremental Revenue Growth Opportunity by Drugs, 2024 – 2032 52
FIG NO. 12. Peptic Ulcer Drugs Market Revenue, By Drugs, 2018, 2023, 2027 & 2032 53
FIG NO. 13. Global Peptic Ulcer Drugs Market for Proton Pump Inhibitor, Volume & Revenue (Unit) (USD Million) 2018 – 2032 54
FIG NO. 14. Global Peptic Ulcer Drugs Market for H2 Antagonists, Volume & Revenue (Unit) (USD Million) 2018 – 2032 56
FIG NO. 15. Global Peptic Ulcer Drugs Market for Antibiotics, Volume & Revenue (Unit) (USD Million) 2018 – 2032 58
FIG NO. 16. Global Peptic Ulcer Drugs Market for Others, Volume & Revenue (Unit) (USD Million) 2018 – 2032 60
FIG NO. 17. Global Peptic Ulcer Drugs Market for Drugs 5, Volume & Revenue (Unit) (USD Million) 2018 – 2032 62
FIG NO. 18. Peptic Ulcer Drugs Market Volume Share, By Types, 2023 & 2032 65
FIG NO. 19. Peptic Ulcer Drugs Market Revenue Share, By Types, 2023 & 2032 65
FIG NO. 20. Market Attractiveness Analysis, By Types 66
FIG NO. 21. Incremental Revenue Growth Opportunity by Types, 2024 – 2032 66
FIG NO. 22. Peptic Ulcer Drugs Market Revenue, By Types, 2018, 2023, 2027 & 2032 67
FIG NO. 23. Global Peptic Ulcer Drugs Market for Gastric Ulcer, Volume & Revenue (Unit) (USD Million) 2018 – 2032 68
FIG NO. 24. Global Peptic Ulcer Drugs Market for Duodenal Ulcer, Volume & Revenue (Unit) (USD Million) 2018 – 2032 70
FIG NO. 25. Global Peptic Ulcer Drugs Market Volume Share, By Region, 2023 & 2032 73
FIG NO. 26. Global Peptic Ulcer Drugs Market Revenue Share, By Region, 2023 & 2032 73
FIG NO. 27. Market Attractiveness Analysis, By Region 74
FIG NO. 28. Incremental Revenue Growth Opportunity by Region, 2024 – 2032 74
FIG NO. 29. Peptic Ulcer Drugs Market Revenue, By Region, 2018, 2023, 2027 & 2032 75
FIG NO. 30. North America Peptic Ulcer Drugs Market Volume & Revenue, 2018 – 2032 (Unit) (USD Million) 81
FIG NO. 31. Europe Peptic Ulcer Drugs Market Volume & Revenue, 2018 – 2032 (Unit) (USD Million) 91
FIG NO. 32. Asia Pacific Peptic Ulcer Drugs Market Volume & Revenue, 2018 – 2032 (Unit) (USD Million) 101
FIG NO. 33. Latin America Peptic Ulcer Drugs Market Volume & Revenue, 2018 – 2032 (Unit) (USD Million) 111
FIG NO. 34. Middle East Peptic Ulcer Drugs Market Volume & Revenue, 2018 – 2032 (Unit) (USD Million) 121
FIG NO. 35. Africa Peptic Ulcer Drugs Market Volume & Revenue, 2018 – 2032 (Unit) (USD Million) 131

List of Tables
TABLE NO. 1. : Global Peptic Ulcer Drugs Market: Snapshot 28
TABLE NO. 2. : Drivers for the Peptic Ulcer Drugs Market: Impact Analysis 33
TABLE NO. 3. : Restraints for the Peptic Ulcer Drugs Market: Impact Analysis 35
TABLE NO. 4. : Global Proton Pump Inhibitor Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 51
TABLE NO. 5. : Global Proton Pump Inhibitor Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 51
TABLE NO. 6. : Global H2 Antagonists Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 53
TABLE NO. 7. : Global H2 Antagonists Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 53
TABLE NO. 8. : Global Antibiotics Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 55
TABLE NO. 9. : Global Antibiotics Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 55
TABLE NO. 10. : Global Others Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 57
TABLE NO. 11. : Global Others Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 57
TABLE NO. 12. : Global Drugs 5 Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 59
TABLE NO. 13. : Global Drugs 5 Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 59
TABLE NO. 14. : Global Gastric Ulcer Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 65
TABLE NO. 15. : Global Gastric Ulcer Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 65
TABLE NO. 16. : Global Duodenal Ulcer Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 67
TABLE NO. 17. : Global Duodenal Ulcer Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 67
TABLE NO. 18. : Global Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2018 – 2023 (Unit) (USD Million) 72
TABLE NO. 19. : Global Peptic Ulcer Drugs Market Volume & Revenue, By Region, 2024 – 2032 (Unit) (USD Million) 72
TABLE NO. 20. : Global Peptic Ulcer Drugs Market Volume & Revenue, By Drugs, 2018 – 2023 (Unit) (USD Million) 73
TABLE NO. 21. : Global Peptic Ulcer Drugs Market Volume & Revenue, By Drugs, 2024 – 2032 (Unit) (USD Million) 73
TABLE NO. 22. : Global Peptic Ulcer Drugs Market Volume & Revenue, By Types, 2018 – 2023 (Unit) (USD Million) 74
TABLE NO. 23. : Global Peptic Ulcer Drugs Market Volume & Revenue, By Types, 2024 – 2032 (Unit) (USD Million) 74
TABLE NO. 24. : Global Peptic Ulcer Drugs Market Volume & Revenue, By Distribution Channel, 2018 – 2023 (Unit) (USD Million) 75
TABLE NO. 25. : Global Peptic Ulcer Drugs Market Volume & Revenue, By Distribution Channel, 2024 – 2032 (Unit) (USD Million) 76
TABLE NO. 26. : North America Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2023 (Unit) 78
TABLE NO. 27. : North America Peptic Ulcer Drugs Market Volume, By Country, 2024 – 2032 (Unit) 78
TABLE NO. 28. : North America Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 79
TABLE NO. 29. : North America Peptic Ulcer Drugs Market Revenue, By Country, 2024 – 2032 (USD Million) 79
TABLE NO. 30. : North America Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 80
TABLE NO. 31. : North America Peptic Ulcer Drugs Market Volume, By Drugs, 2024 – 2032 (Unit) 80
TABLE NO. 32. : North America Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 81
TABLE NO. 33. : North America Peptic Ulcer Drugs Market Revenue, By Drugs, 2024 – 2032 (USD Million) 81
TABLE NO. 34. : North America Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 82
TABLE NO. 35. : North America Peptic Ulcer Drugs Market Volume, By Types, 2024 – 2032 (Unit) 82
TABLE NO. 36. : North America Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 83
TABLE NO. 37. : North America Peptic Ulcer Drugs Market Revenue, By Types, 2024 – 2032 (USD Million) 83
TABLE NO. 38. : North America Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 84
TABLE NO. 39. : North America Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2024 – 2032 (Unit) 84
TABLE NO. 40. : North America Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 85
TABLE NO. 41. : North America Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 85
TABLE NO. 42. : Europe Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2023 (Unit) 88
TABLE NO. 43. : Europe Peptic Ulcer Drugs Market Volume, By Country, 2024 – 2032 (Unit) 88
TABLE NO. 44. : Europe Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 89
TABLE NO. 45. : Europe Peptic Ulcer Drugs Market Revenue, By Country, 2024 – 2032 (USD Million) 89
TABLE NO. 46. : Europe Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 90
TABLE NO. 47. : Europe Peptic Ulcer Drugs Market Volume, By Drugs, 2024 – 2032 (Unit) 90
TABLE NO. 48. : Europe Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 91
TABLE NO. 49. : Europe Peptic Ulcer Drugs Market Revenue, By Drugs, 2024 – 2032 (USD Million) 91
TABLE NO. 50. : Europe Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 92
TABLE NO. 51. : Europe Peptic Ulcer Drugs Market Volume, By Types, 2024 – 2032 (Unit) 92
TABLE NO. 52. : Europe Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 93
TABLE NO. 53. : Europe Peptic Ulcer Drugs Market Revenue, By Types, 2024 – 2032 (USD Million) 93
TABLE NO. 54. : Europe Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 94
TABLE NO. 55. : Europe Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2024 – 2032 (Unit) 94
TABLE NO. 56. : Europe Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 95
TABLE NO. 57. : Europe Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 95
TABLE NO. 58. : Asia Pacific Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2023 (Unit) 98
TABLE NO. 59. : Asia Pacific Peptic Ulcer Drugs Market Volume, By Country, 2024 – 2032 (Unit) 98
TABLE NO. 60. : Asia Pacific Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 99
TABLE NO. 61. : Asia Pacific Peptic Ulcer Drugs Market Revenue, By Country, 2024 – 2032 (USD Million) 99
TABLE NO. 62. : Asia Pacific Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 100
TABLE NO. 63. : Asia Pacific Peptic Ulcer Drugs Market Volume, By Drugs, 2024 – 2032 (Unit) 100
TABLE NO. 64. : Asia Pacific Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 101
TABLE NO. 65. : Asia Pacific Peptic Ulcer Drugs Market Revenue, By Drugs, 2024 – 2032 (USD Million) 101
TABLE NO. 66. : Asia Pacific Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 102
TABLE NO. 67. : Asia Pacific Peptic Ulcer Drugs Market Volume, By Types, 2024 – 2032 (Unit) 102
TABLE NO. 68. : Asia Pacific Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 103
TABLE NO. 69. : Asia Pacific Peptic Ulcer Drugs Market Revenue, By Types, 2024 – 2032 (USD Million) 103
TABLE NO. 70. : Asia Pacific Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 104
TABLE NO. 71. : Asia Pacific Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2024 – 2032 (Unit) 104
TABLE NO. 72. : Asia Pacific Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 105
TABLE NO. 73. : Asia Pacific Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 105
TABLE NO. 74. : Latin America Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2023 (Unit) 108
TABLE NO. 75. : Latin America Peptic Ulcer Drugs Market Volume, By Country, 2024 – 2032 (Unit) 108
TABLE NO. 76. : Latin America Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 109
TABLE NO. 77. : Latin America Peptic Ulcer Drugs Market Revenue, By Country, 2024 – 2032 (USD Million) 109
TABLE NO. 78. : Latin America Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 110
TABLE NO. 79. : Latin America Peptic Ulcer Drugs Market Volume, By Drugs, 2024 – 2032 (Unit) 110
TABLE NO. 80. : Latin America Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 111
TABLE NO. 81. : Latin America Peptic Ulcer Drugs Market Revenue, By Drugs, 2024 – 2032 (USD Million) 111
TABLE NO. 82. : Latin America Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 112
TABLE NO. 83. : Latin America Peptic Ulcer Drugs Market Volume, By Types, 2024 – 2032 (Unit) 112
TABLE NO. 84. : Latin America Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 113
TABLE NO. 85. : Latin America Peptic Ulcer Drugs Market Revenue, By Types, 2024 – 2032 (USD Million) 113
TABLE NO. 86. : Latin America Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 114
TABLE NO. 87. : Latin America Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2024 – 2032 (Unit) 114
TABLE NO. 88. : Latin America Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 115
TABLE NO. 89. : Latin America Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 115
TABLE NO. 90. : Middle East Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2023 (Unit) 118
TABLE NO. 91. : Middle East Peptic Ulcer Drugs Market Volume, By Country, 2024 – 2032 (Unit) 118
TABLE NO. 92. : Middle East Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 119
TABLE NO. 93. : Middle East Peptic Ulcer Drugs Market Revenue, By Country, 2024 – 2032 (USD Million) 119
TABLE NO. 94. : Middle East Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 120
TABLE NO. 95. : Middle East Peptic Ulcer Drugs Market Volume, By Drugs, 2024 – 2032 (Unit) 120
TABLE NO. 96. : Middle East Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 121
TABLE NO. 97. : Middle East Peptic Ulcer Drugs Market Revenue, By Drugs, 2024 – 2032 (USD Million) 121
TABLE NO. 98. : Middle East Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 122
TABLE NO. 99. : Middle East Peptic Ulcer Drugs Market Volume, By Types, 2024 – 2032 (Unit) 122
TABLE NO. 100. : Middle East Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 123
TABLE NO. 101. : Middle East Peptic Ulcer Drugs Market Revenue, By Types, 2024 – 2032 (USD Million) 123
TABLE NO. 102. : Middle East Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 124
TABLE NO. 103. : Middle East Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2024 – 2032 (Unit) 124
TABLE NO. 104. : Middle East Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 125
TABLE NO. 105. : Middle East Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 125
TABLE NO. 106. : Africa Peptic Ulcer Drugs Market Volume, By Country, 2018 – 2023 (Unit) 128
TABLE NO. 107. : Africa Peptic Ulcer Drugs Market Volume, By Country, 2024 – 2032 (Unit) 128
TABLE NO. 108. : Africa Peptic Ulcer Drugs Market Revenue, By Country, 2018 – 2023 (USD Million) 129
TABLE NO. 109. : Africa Peptic Ulcer Drugs Market Revenue, By Country, 2024 – 2032 (USD Million) 129
TABLE NO. 110. : Africa Peptic Ulcer Drugs Market Volume, By Drugs, 2018 – 2023 (Unit) 130
TABLE NO. 111. : Africa Peptic Ulcer Drugs Market Volume, By Drugs, 2024 – 2032 (Unit) 130
TABLE NO. 112. : Africa Peptic Ulcer Drugs Market Revenue, By Drugs, 2018 – 2023 (USD Million) 131
TABLE NO. 113. : Africa Peptic Ulcer Drugs Market Revenue, By Drugs, 2024 – 2032 (USD Million) 131
TABLE NO. 114. : Africa Peptic Ulcer Drugs Market Volume, By Types, 2018 – 2023 (Unit) 132
TABLE NO. 115. : Africa Peptic Ulcer Drugs Market Volume, By Types, 2024 – 2032 (Unit) 132
TABLE NO. 116. : Africa Peptic Ulcer Drugs Market Revenue, By Types, 2018 – 2023 (USD Million) 133
TABLE NO. 117. : Africa Peptic Ulcer Drugs Market Revenue, By Types, 2024 – 2032 (USD Million) 133
TABLE NO. 118. : Africa Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2018 – 2023 (Unit) 134
TABLE NO. 119. : Africa Peptic Ulcer Drugs Market Volume, By Distribution Channel, 2024 – 2032 (Unit) 134
TABLE NO. 120. : Africa Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135
TABLE NO. 121. : Africa Peptic Ulcer Drugs Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135

Frequently Asked Question:

What is the market size of the peptic ulcer drugs market in 2023 and 2032, and what is the CAGR?

The peptic ulcer drugs market is projected to grow from USD 5,321.98 million in 2023 to USD 8,115.68 million by 2032, with a CAGR of 4.80% from 2024 to 2032.

What factors are driving the growth of the peptic ulcer drugs market?

The market is driven by a rising prevalence of peptic ulcers, an aging population, and advancements in drug formulations and delivery systems.

Which geographical region dominates the peptic ulcer drugs market?

North America currently leads the market due to high healthcare expenditure and awareness, with Europe and Asia-Pacific following closely.

Why are combination therapies gaining popularity in the peptic ulcer drugs market?

Combination therapies are effective in treating H. pylori infections and combat antibiotic resistance, making them a preferred choice in managing peptic ulcers.

What role does H. pylori play in the demand for peptic ulcer drugs?

H. pylori infections are a major cause of peptic ulcers, and addressing these infections is critical, driving demand for targeted and combination therapies.

Who are the key players in the peptic ulcer drugs market?

Key players include AstraZeneca, Takeda Pharmaceutical Company, Pfizer Inc., and Abbott Laboratories, all investing in research to maintain their market position.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –